$6.87
0.00% today
Nasdaq, Apr 02, 08:47 pm CET
ISIN
US7458481014
Symbol
LUNG

ProLung Inc Stock price

$6.87
-1.42 17.13% 1M
-0.61 8.16% 6M
+0.08 1.18% YTD
-2.26 24.75% 1Y
-18.82 73.26% 3Y
-12.13 63.84% 5Y
-12.13 63.84% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
+0.14 2.08%
ISIN
US7458481014
Symbol
LUNG
Sector

Key metrics

Market capitalization $273.40m
Enterprise Value $228.13m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.72
P/S ratio (TTM) P/S ratio 3.26
P/B ratio (TTM) P/B ratio 3.19
Revenue growth (TTM) Revenue growth 22.01%
Revenue (TTM) Revenue $83.79m
EBIT (operating result TTM) EBIT $-55.99m
Free Cash Flow (TTM) Free Cash Flow $-32.98m
Cash position $101.74m
EPS (TTM) EPS $-1.44
P/E forward negative
P/S forward 2.82
EV/Sales forward 2.35
Short interest 4.14%
Show more

Is ProLung Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

ProLung Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a ProLung Inc forecast:

5x Buy
71%
2x Hold
29%

Analyst Opinions

7 Analysts have issued a ProLung Inc forecast:

Buy
71%
Hold
29%

Financial data from ProLung Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
84 84
22% 22%
100%
- Direct Costs 22 22
21% 21%
26%
62 62
22% 22%
74%
- Selling and Administrative Expenses 100 100
10% 10%
120%
- Research and Development Expense 16 16
12% 12%
19%
-54 -54
8% 8%
-65%
- Depreciation and Amortization 1.59 1.59
46% 46%
2%
EBIT (Operating Income) EBIT -56 -56
10% 10%
-67%
Net Profit -56 -56
7% 7%
-67%

In millions USD.

Don't miss a Thing! We will send you all news about ProLung Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ProLung Inc Stock News

Neutral
GlobeNewsWire
about one month ago
PDF Version LYON, France, March 3, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Glen French to its Board of Directors.          “We are pleased to welcome Glen to our Board of Directors," said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS.
Neutral
Seeking Alpha
about one month ago
Pulmonx Corporation (NASDAQ:LUNG ) Q4 2024 Results Conference Call February 19, 2025 4:30 PM ET Company Participants Elizabeth Sparicio - Investor Relations Steve Williamson - President and Chief Executive Officer Mehul Joshi - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Jon Young - Canaccord Larry Biegelsen - Wells Fargo Joanne Wuensch - Ci...
Neutral
GlobeNewsWire
about one month ago
REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2024.
More ProLung Inc News

Company Profile

Pulmonx Corp. provides interventional pulmonology, planning tools, and treatments for obstructive lung diseases. It carries out its operations in the following geographical locations: Europe, Middle East and Africa (EMEA), Asia Pacific, Other International, and United States. It offers the Zephyr Endobronchial Valve, an implantable device used to occlude all airways feeding the hyperinflated lobe of a lung that is most diseased with emphysema. It also offers StratX Lung Analysis, a platform designed to treat severe emphysema, and the Chartis Assessment System, a pulmonary assessment system. The company was founded by Rodney C. Perkins and is headquartered in Redwood City, CA.

Head office United States
CEO Steven Williamson
Employees 291
Founded 1995
Website www.pulmonx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today